The country of origin of Clobetasol Propionate Topical Solution, 0.05% (ANDA 076977)
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- In this case, we find the mixing of the active ingredient, Clobetasol Propionate (made in Italy) with the inactive ingredients into the final dosage Clobetasol Propionate Topical Solution in India does not result in a substantial transformation and the country of origin will be Italy.
Ruling text
In your letter dated November 15, 2024, on behalf of Encube Ethicals Private Limited, you requested a country of origin ruling on Clobetasol Propionate Topical Solution, 0.05%. Clobetasol Propionate Topical Solution, 0.05%, imported in 25 mL and 50 mL bottles, is a synthetic corticosteroid. It is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
You stated that the active pharmaceutical ingredient (API), Clobetasol Propionate, is made in Italy, and that the finished topical solution in dosage form is made in India. In India, the Clobetasol Propionate will be mixed with various inactive ingredients to produce the final Clobetasol Propionate Topical Solution in dosage form.
Section 134.1(b), Customs Regulations (19 CFR 134.1(b)), defines "country of origin" as: The country of manufacture, production or growth of any article of foreign origin entering the United States. Further work or material added to an article in another country must effect a substantial transformation in order to render such other country the "country of origin" within the meaning of this part; ….
A substantial transformation occurs when an article emerges from a process with a new name, character or use different from that possessed by the article prior to processing. A substantial transformation will not result from a minor manufacturing or combining process that leaves the identity of the article intact. See United States v. Gibson-Thomsen Co., 27 C.C.P.A. 267 (1940); and National Juice Products Association v. United States, 628 F. Supp. 978 (Ct. Int’l Trade 1986).
In this case, we find the mixing of the active ingredient, Clobetasol Propionate (made in Italy) with the inactive ingredients into the final dosage Clobetasol Propionate Topical Solution in India does not result in a substantial transformation and the country of origin will be Italy. You also submitted pictures of labels for our review. Based upon the labels provided, the subject product does not appear to be legally marked with the proper country of origin.
The labels state the product is manufactured in India and distributed in the United States. However, the country of origin is Italy where the API is made and should be marked “Made in”,” Product of,” or other words of similar meaning with “Italy” as the country of origin.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov.
The holding set forth above applies only to the specific factual situation and merchandise description as identified in the ruling request. This position is clearly set forth in Title 19, Code of Federal Regulations (CFR), Section 177.9(b)(1).
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N344060).